App-Quantinova.ai

Non‐invasive assessment of Paediatric Liver Disease with Multi‐Parametric MRI

Kamil Janowski - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Wilson disease

N/A

Multi‐platform metabonomics reveals a distinct metabolic phenotype of acute‐on‐chronic liver failure

Rabiya Zia - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Acute on chronic liver failure

N/A

Significant lung injury and its prognostic significance in acute liver failure

Constantine J. Karvellas - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Fulminant hepatic failure

N/A

PD‐1 expression in the peripheral blood and the liver of patients with alcoholic hepatitis is impaired and may contribute to disease pathogenesis

Laura J. Blackmore - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Alcoholic hepatitis

N/A

Elena Palma - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

N/A

Time course of treatment‐emergent adverse events (TEAEs) in the randomized, controlled phase 3 RESORCE trial of regorafenib for patients with hepatocellular carcinoma progressing on sorafenib treatment

Philippe Merle - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Regorafenib

Circulating Tumour Cell (CTC) biomarkers and the stratification of therapy for patients with hepatocellular carcinoma

Misti V. McCain - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Liver cancer

N/A

Arndt Voaei - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Lenvatinib

HBV‐specific T cell immunity in inactive carrier patients is independent of Hepatitis B surface antigen load

Upkar S. Gill - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Weight based ribavirin with sofosbuvir and daclatasvir for 12 weeks for patients with Genotype 3 Hepatitis C and cirrhosis: An analysis of efficacy and long‐term clinical outcomes

Chiara Mazzarelli - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Hepatitis C

daclatasvir

Population pharmacokinetic analysis of ledip‐ asvir in patients with decompensated cirrhosis ‐ results from the UK Expanded Access programme

Omar El-Sherif - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

Sofosbuvir/ledipasvir

Does age matter? Direct‐acting antiviral therapy for hepatitis C in a real‐life cohort of elderly patients: pretreatment drug‐drug interactions, tolerability and efficacy of current treatment regimens

Chiara Mazzarelli - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Impact of Comorbidities and Comedications on the Effectiveness of Ombitasvir/Parita‐ previr/Ritonavir ± Dasabuvir ± Ribavirin in Clinical Practice: Real‐World Evidence From a Multicountry Postmarketing Observational Study

Stefan Bourgeois - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

ombitasvir

Real‐world effectiveness and cost per svr of sofosbuvir/velpatasvir chronic hepatitis c treatment

Peter Buaaisch - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Velpatasvir/sofosbuvir

Are we done with the immunohistochemical classification of hepatocellular adenoma?

Anne Aurlie Raymond - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Effect of eGFR at time of liver transplantation on post‐transplant renal and patient outcomes

Shuet Fong Neong - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Proximity to transplant centre does not affect outcome among UK liver transplant patients

Gwilym Webb - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

The impact of new‐onset diabetes mellitus after transplantation (NODAT) on post‐liver transplant outcomes ‐ the largest non‐registry study

Aloysious D. Aravinthan - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

New-Onset Diabetes after Transplantation

N/A

Development of Heparin‐Induced Thrombocytopenia in patients transplanted for Budd‐ Chiari Syndrome is associated with early and late post‐transplant outcomes

Ana Margarida Vaz - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Thrombocytopenia

Heparin

Everolimus Post Liver Transplantation: A Systematic Review

Khalid I. Bzeizi - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Everolimus

Filters

45280 Abstracts